Detection technologies of circulating tumor cells

doi:10.3760/cma.j.issn.1673-422X.2016.05.012

Abstract

Abstract: Circulating tumor cells (CTCs) detections have unique advantages in the realtime personalized medicine of patients with tumors. The rarity and heterogeneity of CTCs in peripheral blood pose great technical challenge for CTCs researches. Most of technologies for detecting CTCs have been developed to enrich CTCs by virtue of physical properties or specific biological features of the cells at first, then genotype or phenotype analysis are performed to count or characterize CTCs. Advances in molecular analysis of single cells enable CTCs detections to provide more accurate and comprehensive information. Biological processes during CTCs invasion and metastasis such as epithelialmesenchymal transition and clustering should to be considered seriously to promote the clinical applications of CTCs detection.

Key words: Neoplasms circulating cells, Detection technology, Epithelialmesenchymal transition

Li Shuling, Liu Jing, Wei Wenqing. Detection technologies of circulating tumor cells[J]. Journal of International Oncology, 2016, 43(5): 368-371.

References

［1］ Yu M, Bardia A, Aceto N, et al. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility［J］. Science, 2014, 345(6193): 216-220. DOI: 10.1126/science.1253533. ［2］ Krebs MG, Metcalf RL, Carter L, et al. Molecular analysis of circulating tumour cellsbiology and biomarkers［J］. Nat Rev Clin Oncol, 2014, 11(3): 129-144. DOI: 10.1038/nrclinonc.2013.253. ［3］ Reyes EE, Vanderweele DJ, Isikbay M, et al. Quantitative characterization of androgen receptor protein expression and cellular localization in circulating tumor cells from patients with metastatic castrationresistant prostate cancer［J］. J Transl Med, 2014, 12: 313. DOI: 10.1186/s129670140313z. ［4］ Huang CH, Wick JA, Sittampalam GS, et al. A multicenter pilot study examining the role of circulating tumor cells as a bloodbased tumor marker in patients with extensive smallcell lung cancer［J］. Front Oncol, 2014, 4: 271. DOI: 10.3389/fonc.2014.00271. eCollection 2014. ［5］ Toss A, Mu Z, Fernandez S, et al. CTC enumeration and characterization: moving toward personalized medicine［J］. Ann Transl Med, 2014, 2(11): 108. DOI: 10.3978/j.issn.23055839.2014.09.06. ［6］ Harouaka R, Kang Z, Zheng SY, et al. Circulating tumor cells:advances in isolation and analysis, and challenges for clinical applications［J］. Pharmacol Ther, 2014, 141(2): 209-221. DOI: 10.1016/j.pharmthera.2013.10.004. ［7］ Ozkumur E, Shah AM, Ciciliano JC, et al. Inertial focusing for tumor antigendependent and independent sorting of rare circulating tumor cells［J］. Sci Transl Med, 2013, 5(179): 179ra47. DOI: 10.1126/scitranslmed.3005616. ［8］ SaucedoZeni N, Mewes S, Niestroj RA, et al. A novel method for the in vivo isolation of circulating tumor cells from peripheral blood of cancer patients using a functionalized and structured medical wire［J］. Int J Oncol, 2012, 41(4): 1241-1250. DOI: 10.3892/ijo.2012.1557. ［9］ Marrinucci D, Bethel K, Kolatkar A, et al. Fluid biopsy in patients with metastatic prostate, pancreatic and breast cancers［J］. Phys Biol, 2012, 9(1): 016003. DOI: 10.1088/14783975/9/1/016003. ［10］ Stott SL, Lee RJ, Nagrath S, et al. Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer［J］. Sci Transl Med, 2010, 2(25): 25ra23. DOI: 10.1126/scitranslmed.3000403. ［11］ Riethdorf S, Müller V, Zhang L, et al. Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial［J］. Clin Cancer Res, 2010, 16(9): 2634-2645. DOI: 10.1158/10780432.CCR092042. ［12］ AlixPanabières C. EPISPOT assay: detection of viable DTCs/CTCs in solid tumor patients［J］. Recent Results Cancer Res, 2012, 195: 69-76. DOI: 10.1007/9783642281600_6. ［13］ Andreopoulou E, Yang LY, Rangel KM, et al. Comparison of assay methods for detection of circulating tumor cells in metastatic breast cancer: AdnaGen AdnaTest BreastCancer Select/DetectTM versus Veridex CellSearchTM system［J］. Int J Cancer, 2012, 130(7): 1590-1597. DOI: 10.1002/ijc.26111. ［14］ Strati A, KasimirBauer S, Markou A, et al. Comparison of three molecular assays for the detection and molecular characterization of circulating tumor cells in breast cancer［J］. Breast Cancer Res, 2013, 15(2): R20. DOI: 10.1186/bcr3395. ［15］ Sieuwerts AM, Mostert B, BoltDe Vries JA, et al. mRNA and microRNA expression profiles in circulating tumor cells and primary tumors of metastatic breast cancer patients［J］. Clinical Cancer Research, 2011, 17(11): 3600-3618. DOI: 10.1158/10780432.CCR110255. ［16］ Heitzer E, Auer M, Gasch C, et al. Complex tumor genomes inferred from single circulating tumor cells by ArrayCGH and nextGeneration sequencing［J］. Cancer Res, 2013, 73(10): 2965-2975. DOI: 10.1158/00085472.CAN124140. ［17］ Ramskld D, Luo SJ, Wang YC, et al. Fulllength mRNASeq from singlecell levels of RNA and individual circulating tumor cells［J］. Nat Biotechnol, 2012, 30(8): 777-782. DOI: 10.1038/nbt.2282. ［18］ Aceto N, Bardia A, Miyamoto DT, et al. Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis［J］. Cell, 2014, 158(5): 1110-1122. DOI: 10.1016/j.cell.2014.07.013. ［19］ Cho EH, Wendel M, Luttgen M, et al. Characterization of circulating tumor cell aggregates identified in patients with epithelial tumors［J］. Phys Biol, 2012, 9(1): 016001. DOI: 10.1088/14783975/9/1/016001. ［20］ Yu M, Bardia A, Wittner BS, et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition［J］. Science, 2013, 339(6119): 580-584. DOI: 10.1126/science.1228522.

[1]	Niu Ruiqi, Liu Pingping, Du Yingying. Progress in detection and technology applications of minimal residual disease detection in postoperative early stage non-small cell lung cancers [J]. Journal of International Oncology, 2022, 49(10): 623-626.
[2]	Hua Dingchao, Wang Xinyu. MicroRNAs and ovarian cancer [J]. Journal of International Oncology, 2017, 44(8): 615-618.
[3]	Li Xiaoqing, Li Yuanfei. Signaling pathways of epithelialmesenchymal transition in colon cancer [J]. Journal of International Oncology, 2016, 43(5): 385-386.
[4]	Chen Shaohua, Qian Jun. Relationship between epithelial mesenchymal transition and tumor stem cells [J]. Journal of International Oncology, 2016, 43(1): 36-38.
[5]	LI Ming, DENG Fang. Roles of miR200c in tumor diagnosis, metastasis and chemoresistance [J]. Journal of International Oncology, 2015, 42(8): 602-604.
[6]	ZHAO Yi, ZHANG Xing-Xing, XU Min. Research progress of long noncoding RNA in tumor epithelialmesenchymal transition [J]. Journal of International Oncology, 2015, 42(8): 599-601.
[7]	LI Min, GUAN Hong, HU Xin-Rong, WANG Ying, WEI Qian, YANG Qing-Feng. Correlation of YB1 upregulation and epithelialmesenchymal transition during tumorigenesis and progression of cervical carcinoma [J]. Journal of International Oncology, 2015, 42(5): 331-335.
[8]	ZHU Lei, SUI Hua, DENG Wan-Li. Advances in signal transduction pathway regulating EMT in tumor invasion and metastasis [J]. Journal of International Oncology, 2014, 41(3): 172-177.
[9]	HAN Xue, LI Man. MicroRNAs and epithelial mesenchymal transition in cancer [J]. Journal of International Oncology, 2014, 41(12): 881-884.
[10]	GONG Dian-Xia, LI Gui-Xin, LU Zhong, et al. Circulating tumor cell detection technology and its application in non-small cell lung cancer [J]. Journal of International Oncology, 2013, 40(10): 769-771.